Thermo Fisher, NanoPin partner on infectious disease workflows

LabPulse.com staff writers
Feb 13, 2020
2019 04 30 22 11 5866 Bacteria 400

Thermo Fisher Scientific is partnering with infectious disease diagnostic company NanoPin Technologies to develop workflows for liquid chromatography-mass spectrometry (LC-MS).

The partnership will utilize Thermo Fisher's LC-MS technology and NanoPin's diagnostic platform to identify disease-related antigens from patient blood samples, Thermo Fisher said.

The goal is for the companies' combined technologies to lead to the development of sensitive clinical assays for infectious diseases, ultimately reducing time to results.

Latest in Multiple sclerosis
Week in Review: At-home flu testing, asymptomatic monkeypox, telediagnostic accuracy, and more
September 7, 2022
2022 09 01 15 04 0405 Cancer Therapy Targeted 400
NfL IDs patients predisposed to neurotoxic complications
August 31, 2022
Body composition in patients treated with Ozempic
Sponsored
Body composition in patients treated with Ozempic
September 20, 2024
2019 08 02 18 28 8245 Cannabis Marijuana 400
Drug test detects possibly toxic cannabis derivative
July 26, 2022
Related Stories
3 D Monkeypox Infecting Cell Social
PCR
Thermo Fisher Scientific obtains FDA EUA for monkeypox/orthopox virus DNA kit
2019 11 08 01 30 1068 Thermo Fisher Amp 2019 V3 400
Diagnostic Technologies
Thermo Fisher withdraws 2020 annual guidance
2020 01 27 21 38 4451 Lab 2019 Coronavirus Test 400
PCR
FDA grants EUA to Thermo's coronavirus diagnostic test
Body composition in patients treated with Ozempic
Sponsor Content
Body composition in patients treated with Ozempic
More in Multiple sclerosis
Week in Review: At-home flu testing, asymptomatic monkeypox, telediagnostic accuracy, and more
By Leo O'Connor
Dear LabPulse.com member,
September 7, 2022
NfL IDs patients predisposed to neurotoxic complications
By LabPulse.com staff writers
Analyzing blood samples from patients before, during, and after CAR-T cell therapy, Washington University School of Medicine researchers found that levels of neurofilament light chain (NfL) proteins are higher in patients who develop neurotoxic complications.
August 31, 2022
2022 09 01 15 04 0405 Cancer Therapy Targeted 400
3M divides health, oral care division into new business
Its new standalone healthcare business will focus on oral care, wound care, healthcare information technology, and biopharma filtration. The tax-free transaction is expected to close by the end of 2023. 3M's healthcare sector generated approximately $8.6 billion in sales in 2021, according to the company.
July 27, 2022
2020 06 17 15 19 1673 Newspaper 400
Drug test detects possibly toxic cannabis derivative
By LabPulse.com staff writers
Breaking research showcased on Tuesday at AACC 2022 demonstrates that common drug testing methods can do just that.
July 26, 2022
2019 08 02 18 28 8245 Cannabis Marijuana 400
Labcorp NfL test confirms neurodegenerative disease
By LabPulse.com staff writers
The neurofilament light chain (NfL) blood test will allow doctors to identify and verify signs of neurodegenerative disease, enabling physicians to provide a more effective and efficient path to diagnosis and treatment for patients, the firm said.
July 12, 2022
2019 04 30 23 29 0302 Brain 400
Quanterix secures breakthrough device designation for MS test
By LabPulse.com staff writers
Simoa measures NfL in human serum and plasma and is intended to help identify patients with relapsing-remitting MS who are at risk of relapse within four years. The designation comes after a study published March 1 in The Lancet Neurology described the effective use of Simoa to interpret elevated NfL values in MS patients, the company said.
April 24, 2022
2019 07 25 22 25 7960 Lab Blood Plasma 400
Lifespin establishes division in the U.S.
By LabPulse.com staff writers
Lifespin is a deep learning company that is building a diagnostic testing platform based on metabolomics. The company's U.S. subsidiary is incorporated in Delaware and initially based in Boston. Dr. Ali Tinazli, the president and CEO of Lifespin, and Dr. Trevor Hawkins, a Lifespin board member, will lead the operations in the U.S.
April 13, 2022
2022 04 14 13 01 9912 United States Map 400
Siemens' MS assay receives FDA breakthrough designation
By LabPulse.com staff writers
The assay quantitatively measures neurofilament light (NfL), a biomarker for nerve cell injury, in cerebrospinal fluid and blood. It is intended to be used in conjunction with clinical, imaging, and laboratory findings. The assay is designed to help identify adult patients with relapsing MS who are considered lower risk of disease activity.
March 24, 2022
2019 12 03 17 03 9108 Siemens Rsna 2019 400
Agilent acquires Virtual Control's lab AI technology
By LabPulse.com staff writers
Specifically, ACIES will be used with liquid chromatography/mass spectrometry (LC/MS) and gas chromatography and MS (GS/MS) instruments. It automates the labor-intensive task of GS/MS data analysis, improving efficiency in the laboratory workflow from sampling to reporting, Agilent said.
February 16, 2022
2019 05 10 17 42 3167 Lab Doctors Dna 400
BrainChip, NaNose laud progress in breath sample COVID-19 test
By LabPulse.com staff writers
The test incorporates NaNose Medical's sensor array to collect data and BrainChip's Akida artificial intelligence chip to perform the diagnosis, according to the two firms. NaNose's sensory array is based on technology developed at Technion Israel Institute of Technology in Haifa, and has similar sensitivity to minute quantities of volatile organic compounds (VOCs) as a dog's nose.
February 24, 2021
2021 02 25 23 48 3444 Covid Virus Dna Molecule 400
Man's best friend helps train neural network for prostate cancer
By Joseph Constance
Researchers with Medical Detection Dogs of the U.K. studied the olfactory ability of dogs to detect aggressive prostate cancer from urine samples and used it to train an artificial neural network (ANN) to better detect cancer in diagnostics. They found that the cancer-sniffing ability of the canines was just one of several factors that could be used to optimize their neural network.
February 17, 2021
2021 02 17 17 07 0976 Dog Paw Hand 400
LabLynx debuts LIMS for COVID-19 testing
By LabPulse.com staff writers
CovidLiMS is a low-cost, turnkey LIMS that can go from setup to live within two to five days, according to the company. The system addresses the needs of existing clients and labs that need to perform COVID-19 testing but don't have a LIMS, or software suitable for COVID-19 testing, LabLynx said.
April 9, 2020
2019 04 24 23 25 8907 Doctor Computer 400
Page 1 of 2
Next Page